Avisa Pharma, Inc. announced that it has entered into a share subscription and drawdown agreement for an equity line of funding with GEM Global Yield Fund LLC SCS, a fund managed by Global Emerging Markets for gross proceeds of CAD 52,000,000 on January 23, 2020. The company will raise the funding over a period of 36 months in multiple tranches The transaction will come in effect in the event that the company becomes listed on any nationally recognized stock exchange or completes a reverse takeover transaction. The investor will not hold more than 19.9% stake in the company through this transaction. The company will pay the investor CAD 1,000,000 as fees through issuance of a promissory note.